This week in therapeutics




Licensing status

Publication and contact information

Endocrine/metabolic disease

Diabetes; obesity

Inhibitor of k-light polypeptide gene enhancer in B cells kinase-e (IKBKE; IKK-i); TANK-binding kinase 1 (TBK1)

Mouse and in vitro studies suggest the generic drug amlexanox could help treat obesity and obesity-related metabolic disorders such as diabetes. In mice fed a high-fat diet, Ikbke and Tbk1 expression was greater than that in mice fed a normal diet. In vitro dose-response studies showed that amlexanox inhibited IKBKE and TBK1 with IC50 values of 1-2 mM. In mouse models for diet-induced obesity, amlexanox increased insulin sensitivity and decreased both hepatic steatosis and adipose tissue inflammation compared with vehicle. Next steps could include clinical trials to evaluate amlexanox in patients.
Amlexanox is a generic drug marketed to treat aphthous ulcers and asthma.

SciBX 6(9); doi:10.1038/scibx.2013.216
Published online March 7, 2013

Patent and licensing status unavailable

Reilly, S.M. et al. Nat. Med.; published online Feb. 10, 2013;
Contact: Alan R. Saltiel, University of Michigan, Ann Arbor, Mich.